IVT-25 Pneumococcal Vaccine Description
IVT-25 is a 25 valent pneumococcal conjugate vaccine (PCV), designed to include the key strains that cause serious invasive disease in children, particularly in Africa and in other low- and middle-income countries.
The investigational vaccine leverages Inventprise’s novel and proprietary linker platform technology which is designed to elicit significantly higher immune responses compared to existing technologies.
The platform allows Inventprise vaccines to potentially increase the breadth of protection over that of current PCVs without compromising the immune response, a challenge not currently addressed by conventional technologies.
Inventprise has generated preclinical data demonstrating the superiority of IVT-25 compared to currently licensed vaccines in head-to-head studies. Inventprise expects to advance IVT-25 into first-in-human clinical trials in the second half of 2022.
Inventprise is a biopharmaceutical company leveraging its innovative platform technology to develop vaccines against infectious diseases, with an initial focus on invasive pneumococcal disease.
Inventprise platform technologies are designed to enable high valent vaccines to induce broad, robust, and durable protection against pathogenic strains of infectious diseases.
IVT-25 Pneumococcal Vaccine Indication
IVT-25 is indicated to prevent pneumococcal bacterial infections.
IVT-25 Pneumococcal Vaccine News
November 10, 2021 - The Bill and Melinda Gates Foundation announced an investment of up to $90 million to support the development activities through the completion of Phase 1 and Phase 2 clinical studies to assess the safety and immunological proof-of-concept.
IVT-25 Pneumococcal Vaccine Clinical Trials
IVT-25 expects the first-in-human clinical trials to begin in the second half of 2022.